Celldex Therapeutics, Inc.
CLDX Nasdaq· In Vitro & In Vivo Diagnostic Substances
Last close · Oct 26, 2026
$29.50
KIRA · Stoqly’s AI analyst, in plain words
- Celldex Therapeutics, Inc. had $1.5M of revenue in fiscal 2025, down 78.0% on the year before. Over five years, revenue changed −26.9% a year on average.
- Its operating margin was −18,599.8%, down 15,820.9 pts: of every 100 in sales, about −18,600 is left after running the business.
- Celldex Therapeutics, Inc. lost $259M in fiscal 2025.
- Free cash flow was −$214M in fiscal 2025, −13,829.1% of revenue.
Market cap
$2.3B
P/E
—
Revenue
$1.5M
Net income
−$259M
Free cash flow
−$214M
Operating margin
−18,599.8%
Celldex Therapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−78.0%
No. Sales fell 78.0% last year.
Does it make a profit?
−16,748.0%
No. It lost money last year.
Does profit turn into cash?
−13,829.1%
No. It spent more cash than it brought in.
How healthy are the accounts?
1 / 8
Weak. It passes 1 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Celldex Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 25, 2026
- Legal name
- Celldex Therapeutics, Inc.
- CIK
- 0000744218
Celldex Therapeutics, Inc. · CLDX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $4.7M | $2.4M | $6.9M | $7.0M | $1.5M |
| Revenue growth | −37.3% | −49.3% | 192.0% | 2.0% | −78.0% |
| Gross margin | 97.8% | 95.8% | 95.6% | 97.2% | 87.1% |
| Operating margin | −1,531.8% | −4,889.0% | −2,245.3% | −2,778.9% | −18,599.8% |
| Net income | −$70.5M | −$112M | −$141M | −$158M | −$259M |
| Net margin | −1,516.0% | −4,765.6% | −2,054.8% | −2,248.8% | −16,748.0% |
| Diluted EPS | −$1.64 | −$2.40 | −$2.92 | −$2.45 | −$3.90 |
| Cash | |||||
| Cash from operations | −$60.9M | −$104M | −$107M | −$158M | −$211M |
| Capital expenditure | $1.2M | $1.8M | $1.8M | $1.9M | $2.7M |
| Free cash flow | −$62.2M | −$106M | −$109M | −$160M | −$214M |
| FCF margin | −1,336.4% | −4,478.6% | −1,585.2% | −2,274.9% | −13,829.1% |
| Share count change | 44.9% | 9.3% | 103,202.8% | 32.9% | 3.1% |
| Debt and strength | |||||
| Cash and short-term investments | $408M | $305M | $424M | $725M | $519M |
| Shareholders' equity | $419M | $326M | $429M | $747M | $527M |
| Current ratio | 24.9x | 17.1x | 13.9x | 18.9x | 10.5x |
| Returns and quality | |||||
| Return on equity | −22.4% | −30.1% | −37.4% | −26.8% | −40.6% |
| Return on tangible equity | −18.0% | −37.6% | −35.2% | −21.9% | −51.8% |
| Piotroski F-score | 4 | 1 | 3 | 4 | 1 |
| Altman Z'' | 13.8 | 4.7 | 6.0 | 15.1 | 1.9 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$1.3M
2 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Celldex Therapeutics, Inc. · CLDX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $29.50 a share, the company is worth $2.3B.
Source: SEC EDGAR XBRL filings (CIK 0000744218). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.